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ABSTRACT
Asthma is the most common chronic paediatric disease
treated in the emergency department (ED). Rapid
corticosteroid administration is associated with
improved outcomes, but our busy ED setting has made
it challenging to achieve this goal. Our primary aim
was to decrease the time to corticosteroid
administration in a large, academic paediatric ED. We
conducted an interrupted time series analysis for
moderate to severe asthma exacerbations of one to 18
year old patients. A multidisciplinary team designed the
intervention of a bedside nurse initiated administration
of oral dexamethasone, to replace the prior system of a
physician initiated order for oral prednisone. Our
baseline and intervention periods were 12 month
intervals. Our primary process measure was the time to
corticosteroid administration. Other process measures
included ED length of stay, admission rate, and rate of
emesis. The balance measures included rate of return
visits to the ED or clinic within five days, as well as the
proportion of discharged patients who were admitted
within five days. No special cause variation occurred in
the baseline period. The mean time to corticosteroid
administration decreased significantly, from 98 minutes
in the baseline period to 59 minutes in the intervention
period (p < 0.01), and showed special cause variation
improvement within two months after the intervention
using statistical process control methodology. We
sustained the improvement and demonstrated a stable
process. The intervention period had a significantly
lower admission rate (p<0.01) and emesis rate
(p<0.01), with no unforeseen harm to patients found
with any of our balance measures. In summary, the
introduction of a nurse initiated, standardized protocol
for corticosteroid therapy for asthma exacerbations in a
paediatric ED was associated with decreased time to
corticosteroid administration, admission rates, and
post-corticosteroid emesis.
PROBLEM
Asthma is the most common chronic disease
of childhood, and accounts for more emer-
gency department (ED) visits than all other
chronic paediatric diseases combined.1
Systemic corticosteroids provide anti-
inflammatory effects and acutely improve
responsiveness to beta agonists.2 Children
presenting to the ED for acute asthma
exacerbations are treated with beta agonists
and systemic corticosteroids. Rapid cortico-
steroid administration is associated with
improved outcomes for patients with asthma
exacerbations.3 Prior to 2007, the ED asthma
pathway in our freestanding children’s hos-
pital included nurse initiated beta agonist
therapy by protocol without a physician
order, but corticosteroids were administered
only after physician evaluation and a written
order.
In multidisciplinary feedback sessions, we
identified the lack of a nurse initiated proto-
col for corticosteroids, lack of standardisation
in the type of corticosteroid, and lack of stan-
dardised dosing of corticosteroids as signifi-
cant barriers to decreasing the time to
steroid administration for asthma patients.
We had administered beta agonists by unit
dose (7.5 mg for children <30 kg, and 15 mg
for larger children), but we administered cor-
ticosteroids on a less standardised milligram
per kilogram basis. The corticosteroid of
choice was either prednisone tablets or pred-
nisolone liquid (depending on age), at 2
mg/kg/day (maximum dose 60 mg per day)
to complete in a five day course. There was a
consensus among ED physicians and nurses
that we could improve our timeliness of care
to our ED patients with acute asthma exacer-
bation. Therefore, we formed a multidiscip-
linary team of ED physicians, ED nurses,
pulmonologists, hospitalists, and pharmacists
to address the problem.
The aim of our project was to decrease the
time from patient arrival to corticosteroid
administration for patients in the ED with
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acute asthma exacerbations, and to measure the second-
ary effects of this intervention on patient outcomes.
We performed this intervention at an urban, aca-
demic, tertiary children’s hospital (Children’s National
Health System in Washington, DC), with an annual ED
volume of approximately 87 000 patients. This ED serves
large numbers of patients living in the inner city who
are uninsured or have state sponsored insurance
(Medicaid), both of which place patients at risk of poor
medical management for their asthma.
BACKGROUND
Corticosteroids are a mainstay for acute asthma exacer-
bation treatment. However, previous studies reported
low adherence to evidence based guidelines in the
provision of systemic steroids for acute asthma exacer-
bation.4 5 A one or two dose course of oral dexametha-
sone has equivalent efficacy to a 5 day course of oral
prednisone/prednisolone for the treatment of acute
asthma exacerbations, as measured by rates of return
for unscheduled care.6 7 8 In other ED settings, early
dosing of corticosteroids, and the use of a clinical
pathway for asthma management in the ED, have each
been associated with improved outcomes.3 9 10 Steroid
administration for acute asthma exacerbations is
delayed during periods of increased ED crowding, sup-
porting the use of giving steroids from triage to reduce
the variation of administration timing caused by high
patient volume in the ED.11 12 Anecdotally, we also
noted vomiting after oral prednisolone in a substantial
number of cases.
In February 2007 we revised our asthma pathway to
incorporate a nurse initiated standing order for the
administration of a weight appropriate dose of oral dexa-
methasone using three weight ranges. In order to
measure the effect of the pathway on patient centred
outcomes, we compared patients treated under the new
pathway to those treated under the old pathway over two
consecutive 12 month periods. We hypothesised that ED
patients with moderate to severe asthma exacerbations
in the new pathway would experience a decrease in the
time from triage to corticosteroid administration, a
decrease in ED length of stay (LOS), a decrease in
admission rates, and a decrease in the rates of emesis.
As reducing hospital admission rates might impact rates
of return to the ED after discharge, we measured
returns to the ED within five days as a balance measure.
BASELINE MEASUREMENT
In order to minimise the confounding effect of the sea-
sonal variability of asthma and ED operations, we chose
to include a random sample of children over each 12
month period in the baseline and intervention periods.
We scheduled the implementation of the modified
pathway for February 2007. We compared treatment of
patients during the 12 month interval starting March
2007 to the treatment of those seen during the 12
month interval immediately prior to implementation.
We measured the change in a process measure (primary
outcome: time from triage to corticosteroid), outcome
measures (emesis rate, ED length of stay for children
not admitted to the hospital, and admission rate), and
three balance measures (unplanned ED return visits for
asthma care within five days, ED return visit with admis-
sion, and unscheduled follow up visits for asthma to the
hospital’s primary care clinics).
To obtain baseline performance, we manually col-
lected data from scanned paper charts and the elec-
tronic tracking board. We abstracted data to determine
the triage time, corticosteroid administration time, ED
length of stay (LOS) from arrival to discharge, ED dis-
position, occurrence of emesis after steroid administra-
tion, and any return visits to the ED. Given the high
volume of patients with acute asthma exacerbations seen
at the ED annually, we obtained a random subset of
charts from the baseline and intervention periods. We
assessed the chart of every eighth patient with a dis-
charge diagnosis of asthma for eligibility; if ineligible, we
assessed the previous chart.
Our baseline time to corticosteroid administration was
98 minutes (standard deviation 65 minutes). We
believed that our intervention could decrease this time
by at least 15 minutes. To detect a decrease of 15
minutes, 336 patients were required in each group to
achieve 80% power in a two sided test with an alpha of
0.05. A run chart was constructed to determine the
process stability of the time to corticosteroid administra-
tion over time during the baseline phase; mean times
for subgroups of 14 consecutive patients were used to
create a run chart with 21 points; special cause rules
included:
(a) ≥6 consecutive points in an increasing or decreas-
ing direction
(b) Above or below the standardised limits for the
number of allowable runs for a set number of
observations
(c) ≥8 points in a run.13
No special cause variation occurred during the base-
line phase (figure 1), and our mean time from triage to
corticosteroid administration was 98 minutes. The results
of our other baseline measures can be seen in table 2.
For our primary outcome during the intervention
phase, we performed an interrupted time series analysis
starting one month after the intervention, using a
Shewhart X bar chart to determine if special cause vari-
ation had occurred, for the monthly mean time to cor-
ticosteroid process during the baseline phase versus the
intervention phase. The special cause rules used
included:
(a) Single point outside control limits of three stand-
ard deviations
(b) Eight points in a row on same side of centre line
(c) Six points in a row, all increasing or decreasing
(d) Two of three consecutive points that are >2 stand-
ard deviations from centre line.14
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During the intervention period, nursing staff were pro-
vided aggregate feedback on time from triage to cortico-
steroid administration approximately every three
months.
We analyzed secondary outcome time interval data
using the student’s t test for normally distributed data,
and the Mann Whitney U test for non-normally distribu-
ted data. We compared proportions using the chi
square. The level of statistical significance was 0.05.
Statistical analyses were performed using Microsoft Excel
(version 2003) and SPSS Statistics 17.0 (SPSS Inc.,
Chicago, IL).
We used three balance measures to determine if
unforeseen consequences were affecting the patients in
the baseline versus the intervention period. First, we
assessed the proportion of unplanned ED return visits
(ie “bouncebacks”) for asthma care within five days of
the original ED visit for those children who were dis-
charged from the ED. Second, we checked the propor-
tion of patients who were discharged from the ED and
had been admitted on their bounceback visit to the ED
within five days of the original ED visit. Third, because
some caregivers might take their child to an alternative
care location for an unscheduled asthma follow up visit,
we calculated the proportion of discharged children
who had unscheduled follow up visits (ie because they
were sick, which is not the same as the routine sched-
uled follow up visits that are recommended with every
ED patient discharged with asthma) to the hospital’s
primary care clinics within five days of the original ED
visit.
The Institutional Review Board at Children’s National
Health System approved this study.
DESIGN
Our team modified the existing asthma pathway by inter-
disciplinary consensus of ED physicians, pulmonologists,
hospitalists, pharmacists, and ED nurses, after a review
of relevant literature and consideration of ED logistics.
We shared the modified pathway with ED physicians
through staff meetings and emails. We educated ED
nurses using in-service education in small groups over
several months. After several rounds of iterative feedback
and changes to ensure feasibility for frontline clinical
providers, we finalised a version of the new asthma
pathway.
The new asthma pathway was provided as a single
page flow diagram and two pre-printed order sheets
(one for children <30 kg and one for children ≥30 kg),
with dosing recommendations for albuterol, ipratro-
pium, and dexamethasone (appendix 2). Key compo-
nents of the pathway that were different than previous
practice included:
1. Nurse initiated orders for corticosteroids
2. Standardisation of the choice of corticosteroids to
dexamethasone
3. Three weight based dose ranges to eliminate the
need for dose calculations
4. Dispensing a second dose of dexamethasone from
the pharmacy for home use prior to discharge.
Nurses were encouraged to administer an initial com-
bined unit dose of albuterol and ipratropium, and a
single dose of dexamethasone, to patients eligible for
the clinical pathway, based on strict inclusion criteria,
exclusion criteria, and patient weight range. Patients
aged one to 18 years with a chief complaint of acute
asthma were included if they had moderate to severe
asthma, as defined by an asthma score of four or greater
on the modified paediatric asthma score. The asthma
score uses five components, each of which are scored
from zero (absent) to two (severe); scores can range
from zero to 10 (appendix 1). Patients were excluded if
they had received systemic corticosteroids within the pre-
vious 24 hours, or if they required intravenous corticos-
teroids in our ED. Dexamethasone was dosed as follows:
Figure 1 Statistical process
control (Xbar) chart of the mean
times to steroid administration in
the baseline (Prednisone) and
intervention (Dexamethasone)
phases.
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<10 kg received 6 mg
10 kg to <20 kg received 12 mg
≥20 kg received 16 mg.
Additional orders, such as home medications or add-
itional doses of albuterol, were ordered by the phys-
ician. Our team pilot tested the order sheets on a few
patients to ensure that the correct wording, content,
and dosages were appropriate for patients with asthma
exacerbations.
By standardising the corticosteroid drug and dosage,
our multidisciplinary group believed that this would
empower our nurses in triage to safely and efficiently
administer therapy. We anticipated that the pathway
might be used less frequently when large numbers of
patients arrived to triage simultaneously, as the ordering
and obtaining of the corticosteroid would add time to
the triage processing time for each asthma patient.
Given the pressure to maintain rapid triage throughput
for the safety of all patients in the ED, we recognised
this as an inherent limitation to a triage based interven-
tion. In response, we provided an option for the bedside
nurse to administer the dexamethasone if the triage
nurse was too busy.
STRATEGY
After several months of project design, feedback, and
education, we implemented our pathway on the first day
of a new month (February 2007). We posted the asthma
scoring system (appendix 1) in all triage areas, and had
the ordering forms (appendix 2) placed in all triage
and treatment areas of the ED. We met with our admin-
istrative assistants to assure that the forms would remain
stocked in the appropriate areas, given our paper based
ordering system. Nursing educators worked with triage
nurses and bedside nursing providers to assure they
understood the new protocol for their patients. They
also verified that they understood the new dosing regi-
mens. Additionally, if physicians went off of the protocol
in ordering a different corticosteroid (eg prednisolone),
or different dosing than the set three dosing levels,
ordering physicians received real time feedback and cor-
rection from the nurse, pharmacist, or available nursing
or physician ED leadership. This system of correcting
orders was intended to be non-punitive in nature, and
helped to fill in any educational gaps from our initial
training in the protocol. Initially on a daily basis, then
on a weekly basis for the first two months, and after-
wards on a monthly basis, members of the quality
improvement team met to discuss informal feedback
they had received from frontline providers on how to
make the process easier to perform. As data was manu-
ally collected with paper charts, the analysis of the pro-
ject’s performance happened approximately once per
quarter. We communicated the collective performance
for our primary aim to our ED nurses and physicians
using email, staff meetings, and shift change huddles in
the ED.
RESULTS
Asthma was the discharge diagnosis in 2785 visits
between 01 February 2006 and 31 January 2007 (base-
line), and 3377 visits between 01 March 2007 and 28
February 2008 (intervention). We reviewed 752 ran-
domly selected patient charts in the baseline group and
756 randomly selected patient charts in the intervention
group to assess study eligibility, and reach our target of
336 patients per group. Patients were most commonly
excluded from the study for asthma scores less than 4
(mild asthma) and age less than 12 months. Baseline
demographics for both groups, including initial asthma
score, had no significant differences (see table 1).
Of the 336 patients included in the baseline group,
316 (94%) received prednisone or prednisolone for
moderate to severe asthma exacerbation, one (<1%)
received dexamethasone, and 19 (5%) did not receive
any corticosteroid. In the intervention group, 333
patients (99%) received dexamethasone, one (<1%)
received prednisone, and two (<1%) did not receive any
corticosteroid.
For the primary outcome, the time to corticosteroid
administration decreased from 98 minutes baseline to
59 minutes in the intervention period (p < 0.01).The X
bar chart (figure 1) showed special cause variation in
this time metric during the intervention phase in month
14 (the second month after the onset of the interven-
tion), and stabilised to indicate a sustained shift in the
process.
For secondary outcomes there were no differences in
median ED LOS between baseline and intervention
groups (259 versus 263 minutes, respectively; p = 0.90). Of
the discharged patients there was also no difference in
median ED LOS between baseline and intervention
groups (303 versus 283 minutes, respectively; p = 0.08).
Admission rates were lower for intervention group sub-
jects (15%) than baseline group subjects (24%) (p <0.01)
(table 2). Emesis after steroid administration was noted in
27 patients (8%) in the baseline group, and no patients
(0%) in the intervention group (p <0.01) (table 3).
Regarding the balance measures, there were no worse
outcomes of balance measures for the patients in the
Table 1 Demographics and initial asthma scores of
patients included in the analysis
Characteristic
Baseline
(n=336)
Intervention
(n=336)
Sex
Male (%)
Female (%)
207 (62)
129 (38)
205 (61)
131 (39)
Age, months, mean +/− s.d. 60±50 76.5±54.8
Weight, kg, mean +/− s.d. 27.2±20.6 29.2±22.5
Initial asthma score
Moderate (%)
Severe (%)
297 (88.4)
39 (11.6)
303 (90.2)
33 (9.8)
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intervention period. Children returned to the ED for
continuing asthma symptoms within five days at similar
rates in both groups (table 2). Likewise, there were no
significant differences between the proportions of dis-
charged patients who returned within five days and were
admitted (table 2). Of the 100 baseline and 110 inter-
vention patients followed at our hospital’s primary care
clinics, there were more unscheduled follow up visits for
asthma in the baseline (22%) than in the intervention
group (12%), p = 0.04; the decrease in this rate supports
the intervention decreasing unscheduled follow up
patients, as patients historically attend these visits if they
are doing worse clinically (See supplementary - appendi-
ces 1 and 2).
LESSONS AND LIMITATIONS
Our primary lessons learned were around the need for a
multidisciplinary buy in for the project, and the need
for standardisation of ordering.15 By engaging with sta-
keholders from all processes in the care of children with
asthma exacerbations, we were able to anticipate poten-
tial barriers to the behaviour changes we were promot-
ing with this project. One challenge we experienced was
getting all of the ED physicians to change their practice
in one of the most common conditions treated in our
ED. Given that each physician had a long history of
treating children with asthma, implementing change
required multiple physician meetings with education
and discussion, to get everyone on board. By using a
single medication and standardising dosing, we elimi-
nated the cognitive load for physicians in determining
both the type and dosage of medicine to order. Because
the nurse and pharmacist double check all medication
dosages, we decreased their cognitive load as well, and
decreased the time required for this step in the process.
One major barrier in the design of this project was the
concept of nurse initiated therapy. This was a concern
by our ED nurses who did not want to be acting outside
of their licensed scope of practice. We were able to over-
come this barrier by engaging with the hospital’s
nursing leadership. The reasons that enabled nursing
leadership to approve of this step was that all physicians
had signed off on the protocol prior to implementation,
we had pre-printed order sheets, and the determination
that ED nurses would be assessing and not diagnosing
children with an established diagnosis of asthma.
This intervention was not associated with an improve-
ment in ED length of stay (LOS). It is possible that time
to obtain the home dexamethasone dose from the phar-
macy contributed to longer LOS in the intervention
group. However, based on frontline user feedback,
nurses have appreciated this change of improved access
to dexamethasone medication, and anecdotally noted
that this helped to decrease the time to administer the
medication to patients.
We were able to demonstrate sustained changes for
one year. Although we do not have intervening data
from the end of this study to today, we can confirm that
the same principles are still in effect, with standardised
dosages of dexamethasone, established first line beta
agonist therapy, and early ordering of dexamethasone.
Our ED has sustained these practices due to the value
that the project adds to the ED healthcare provider and
their patients. We communicated our results to other
regional community EDs, who had a history of transfer-
ring patients with acute asthma exacerbations to our ED
for a higher level of care. Given their strong interest in
adapting the change concepts to their ED, and our sus-
tained improvements in our own ED, we shifted our
focus from trying to set up a new PDSA cycle within our
own ED to helping to spread our intervention to a com-
munity ED. Given our limited available time and
resources to implement quality improvement projects,
we reasoned that a set amount of effort in the commu-
nity ED would yield greater changes in patient out-
comes. After implementing a similar pathway, they
achieved a significant decrease in the time to steroid
administration from 181 to 86 minutes (Walls T et al; in
press). The proportion of asthma exacerbations who
required transfer to a higher level of care was also sig-
nificantly decreased.
Our study had several limitations. Although we
detected differences in several important outcomes
between the baseline and intervention groups, these
observed associations may not necessarily be causally
Table 2 Outcomes:
Characteristic
Baseline
(n=336)
Intervention
(n=336) p-value
Mean time from triage to corticosteroid, minutes 98 59 <0.01
Median length of stay (LOS) 259 263 0.90
Admission, n (%) 79 (24) 49 (15) <0.01
Post-corticosteroid emesis, n (%) 27 (8%) 0 (0%) <0.01
Discharged patients who had a return visit to ED within 5 days, n (%) 11 (4.3%) 17 (5.9%) 0.44
Discharged patients who had a return visit within 5 days requiring
admission, n (%)
6 (2.3%) 2 (0.7%) 0.16
Discharged patients who had an unscheduled follow-up visit at our
hospital’s primary care clinic
22 (22%) 13 (12%) 0.04
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related. However, the statistical process control charts
demonstrate the temporal and significant relationship
between the start of the pathway and the observed
results. Second, we performed this study at a single site
with highly invested nursing staff, among a population
of largely urban, minority, and disadvantaged patients;
thus our results may not be generalisable to other set-
tings. However, we have demonstrated that implementa-
tion of this asthma pathway had similar results for
children treated at a regional community hospital in
which only 25% of patients are paediatric (Walls T et al;
in press). Third, we were not able to assess the variety of
contextual factors that may have affected ED length of
stay, such as the number of patients in the ED at any
given time, number of patients seen by the same phys-
ician delaying medical assessment after initiating treat-
ment, and pharmacy delay in the availability of the
home dose dexamethasone. Finally, when assessing for
relapse, we did not measure return visits to other EDs in
our region; however, Children’s National Health Systems
EDs see more than 85% of all paediatric ED visits for
asthma in Washington, DC, making it less likely that a sig-
nificant number of return visits were missed.17 It is also
unlikely that any rate of missed return visits is systematic-
ally different between baseline and intervention groups.
We did not show a statistically significant difference in ED
LOS in children who were discharged from the ED
between the baseline and intervention groups. ED LOS is
confounded by factors that we were unable to control for,
such as patient volumes and staffing in the ED.
CONCLUSION
Among patients with moderate to severe asthma exacer-
bations in an urban academic paediatric medical centre,
a nurse initiated ED clinical pathway was associated with
improved times from triage to corticosteroid administra-
tion, and a decreased rate of admission to the hospital.
We found no harmful changes in any of our return rates
that served as our balance measures. A decrease in cor-
ticosteroid administration time was our primary aim, and
this did not change throughout the project. We believed
that this primary aim measure would be most directly
affected by changes in our healthcare provider behav-
iour, and less affected by confounders than other mea-
sures in this project.
The improvement in the patient outcome measure, ie a
reduced rate of initial hospitalisation, is consistent with
the known effect of corticosteroids and the improvement
we achieved in our process measure: a reduced time to
corticosteroid administration. A previous Cochrane
review found that corticosteroid administration within
one hour of ED arrival significantly reduced hospital
admissions of patients with acute asthma, particularly
those with more severe asthma.3 Zemek et al performed a
similar study in a large tertiary care children’s hospital in
Canada;16 they demonstrated that nurse initiated corti-
costeroids for acute asthma before physician assessment
reduced LOS and admission rates. However, that study
was limited by the sampling period, which did not
account for seasonal variation in asthma triggers and ED
operations. Furthermore, Zemek at al did not measure
rates of emesis or return ED visits within five days.
No children vomited in the intervention (dexametha-
sone) group. This is consistent with previous studies that
have shown a marked decrease in vomiting in the ED
when dexamethasone is used instead of prednisolone in
children with acute asthma exacerbations.6 It is also sup-
ported by the fact that dexamethasone is known to have
antiemetic properties.18 We used the parenteral formula-
tion of dexamethasone and administered it orally (in
young children) or via oral tablets (in older children),
resulting in a decreased volume of medication com-
pared to weight equivalent dosing of prednisolone.
In our study, as in other studies comparing the use of
dexamethasone versus prednisolone for treatment of
acute asthma exacerbations, there was no significant dif-
ference in the rate of children who returned for an
unscheduled visit to our ED.6 8 One possible explan-
ation for this finding is that the decreased rate of vomit-
ing, and decreased number of doses required when
treated with dexamethasone, may have resulted in
improved compliance with oral corticosteroid therapy.
In summary, initiation of a new ED asthma care
pathway distinguished by nurse initiated administration
of weight based unit dosing of both beta agonists and
dexamethasone was associated with significant decreases
in time to corticosteroid administration, rates of vomit-
ing, and rates of hospital admission among a population
of patients with moderate to severe exacerbations
treated in the ED of a large urban paediatric medical
centre. The long term implications of this project are
still in place today, likely due to the demonstrated
improvements in patient based measures, and the ease
that healthcare providers have when using this new
protocol. Our standardised protocol would likely be rep-
licable and generalisable to other ED settings, and a
community based ED has already demonstrated similar
results to our findings using the same protocol (Walls T
et al; in press).
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